Cardinal Health’s Earnings Call Highlights Broad-Based Upswing
Cardinal Health ((CAH)) has held its Q2 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardinal Health Signals Strong Momentum With Upbeat Earnings Call
Cardinal Health’s latest earnings call struck a distinctly positive tone, highlighting broad-based strength across the business, upgraded earnings guidance, and improving balance sheet metrics. Management emphasized strong revenue and profit growth, margin expansion, and robust cash generation, while downplaying headwinds such as higher interest costs, tariffs, and some temporary boosts in certain segments. Overall, the message was that the company’s growth engines—particularly pharmaceuticals, specialty, and other high-growth platforms—are firmly in motion and outweigh the manageable near-term challenges.
EPS Guidance Raised on Strong First-Half Performance
A central theme of the call was Cardinal Health’s decision to lift its full-year fiscal 2026 non-GAAP diluted EPS guidance to a range of $10.15–$10.35, up from prior expectations of at least $10. This implies a robust year-over-year earnings increase of roughly 23%–26%. Management tied the upgrade to stronger-than-expected performance in the first half, especially in the pharmaceutical and specialty segment, as well as improved confidence in the outlook for the remainder of the year. The move signals that the company not only sees current trends as sustainable but also believes its operational and strategic initiatives are increasingly flowing through to the bottom line.
Double-Digit Revenue Growth and Surging Earnings
Cardinal Health delivered a standout quarter at the consolidated level, with revenue up 19% year-over-year to $66.0 billion. Operating earnings grew an even faster 38% to $877 million, demonstrating operating leverage as the business scales. Non-GAAP diluted EPS climbed 36% to $2.63 compared with $1.93 a year earlier, underscoring strong profitability despite macro and cost pressures. For investors, this combination of high-teens revenue growth and mid-30s earnings growth suggests Cardinal is executing effectively across its core distribution and higher-growth specialty platforms, rather than relying on one-off factors.
Gross Margin Expansion and Tight Cost Discipline
Profitability quality also improved, with gross margin rising 24% to $2.4 billion, outpacing revenue growth. While SG&A expenses increased 16% to $1.5 billion, management highlighted that organic SG&A growth—excluding recent acquisitions—was only in the low single digits. Within the Global Medical Products and Distribution (GNPD) business, SG&A actually declined year-on-year, reflecting progress from ongoing optimization and simplification initiatives. Taken together, Cardinal is managing to grow aggressively while keeping underlying cost growth well contained, a key factor in its margin expansion story.
Pharmaceutical & Specialty Segment Drives the Story
The pharmaceutical and specialty segment remains the cornerstone of Cardinal’s performance. Segment revenue climbed 19% to $61.0 billion, while profit advanced 29% to $687 million, indicating increasing scale and improving mix. GLP-1 therapies—one of the fastest-growing drug categories—contributed roughly six percentage points to the segment’s revenue growth, highlighting Cardinal’s leverage to major therapeutic trends. Management reiterated its expectation that specialty revenues will surpass $50 billion in fiscal 2026, driven by strong generic unit growth and contributions from management services organizations (MSOs), including the recently closed Solaris Health acquisition. This segment is clearly positioned as the company’s key earnings and growth engine.
Other Growth Platforms Outperform: Nuclear, At-Home and Optifreight
Beyond the core pharmaceutical distribution business, Cardinal’s “other growth businesses” are emerging as meaningful profit contributors. Revenue in this bucket increased 34% to $1.7 billion, while segment profit surged 52% to $179 million. Theranostics, an advanced nuclear medicine segment, posted revenue growth above 30%. Meanwhile, Optifreight and At-Home Solutions each delivered revenue growth of around 30%, with the At-Home business benefiting from the ongoing integration of the ADS acquisition. These high-growth adjacencies provide Cardinal with diversified revenue streams and higher-margin opportunities, helping to drive the company’s overall profit mix higher.
GNPD Shows Turnaround Traction
A key area of investor focus—the GNPD segment—continued to show clear signs of recovery. GNPD revenue rose 3% to $3.3 billion, and segment profit more than doubled to $37 million from $18 million a year earlier. U.S. Cardinal Health–branded product revenue grew 10%, supported by operational improvements and supply-chain simplification. Management stressed that the segment’s transformation initiatives are gaining traction, reflected in better service levels, more efficient operations, and a gradually improving margin profile. While GNPD has been a pressure point historically, the latest results suggest a material improvement trend is underway.
Cash Generation and Shareholder Returns Remain Robust
Cardinal’s earnings strength is translating into solid cash flow. Year-to-date adjusted free cash flow reached $1.8 billion, and the company expects to generate between $3.0 billion and $3.5 billion for the full fiscal year. The balance sheet closed the quarter with $2.8 billion in cash and year-to-date capital expenditures of about $240 million, indicating ample capacity for both reinvestment and capital return. So far this year, roughly $1.0 billion has been returned to shareholders—around $250 million via dividends and $750 million through share repurchases, including $375 million of buybacks in the second quarter at an average price of $173. For equity investors, these numbers underscore a disciplined and shareholder-friendly capital allocation strategy.
Improving Leverage Enhances Financial Flexibility
The company’s leverage profile also improved meaningfully. Cardinal’s Moody’s-adjusted leverage ratio fell to 3.2x, returning to the firm’s targeted range of 2.75x–3.25x. Management framed this as an important milestone, restoring balance sheet flexibility for opportunistic deployment of capital—whether toward additional buybacks, dividends, acquisitions, or internal growth investments. For the market, being back inside the leverage target reduces balance sheet risk and supports confidence in the sustainability of Cardinal’s capital return plans.
Operational and Service Enhancements Support Growth
Underpinning the financial performance are tangible operational upgrades. Cardinal cited a 10% improvement in service levels over the past two years, driven by investments in technology, network footprint, and e-commerce capabilities. The Vantas Headquarter e-commerce platform and related technology initiatives were highlighted as key contributors to improved efficiency and a stronger margin profile. These investments are critical for a high-volume distribution business competing on reliability, scale, and data-driven solutions, and they help explain the stronger profitability trends despite industry pricing and cost pressures.
Acquisition-Funded Growth Comes With Higher Interest Costs
One trade-off of Cardinal’s acquisition-led expansion, particularly in specialty and At-Home, has been higher interest expense. Interest and other expense nearly doubled to $77 million in the quarter from $38 million a year ago, driven largely by financing costs associated with recent deals including Solaris Health. While this is a clear drag on net income and EPS, management framed it as a manageable and expected consequence of investing in attractive growth platforms. Over time, the expectation is that earnings contributions from these acquisitions will more than offset the incremental financing costs.
GNPD Timing Benefits Expected to Normalize
Management cautioned that some of GNPD’s recent strength reflects temporary timing dynamics. Roughly 3–4 percentage points of the U.S. Cardinal brand’s 10% growth in GNPD were tied to distributor inventory restocking. This timing-related boost is expected to reverse in the third quarter, creating a headwind as those customers work through elevated inventories. While the underlying GNPD improvement remains intact, investors should anticipate a more normalized growth rate in upcoming quarters as these timing effects wash out.
Tariffs and Pricing Pressure Remain Persistent Headwinds
Despite the broadly positive backdrop, Cardinal is not immune to macro and policy headwinds. In GNPD, tariff-related costs partially offset operational gains, limiting margin upside and remaining an ongoing challenge for the segment. More broadly, management reiterated that manufacturer list price reductions tied to drug pricing reforms are expected to weigh on reported revenue through lower wholesale acquisition costs. However, the company believes existing contractual mechanisms and pricing structures will allow it to preserve margins even as top-line figures face pressure, suggesting that revenue optics may look worse than underlying profitability.
Elevated SG&A and Lower Cash Levels Reflect Investment Mode
While cost discipline is evident on an organic basis, total SG&A rose 16% to $1.5 billion, reflecting the impact of acquisitions and heavier investment spending. Management acknowledged that these factors are pressuring near-term expense levels but argued they are necessary to fuel long-term growth in high-return areas such as specialty, nuclear, and At-Home. At the same time, the company’s $2.8 billion cash balance is at the lower end of its historical range, which may temporarily limit cash flexibility until additional free cash flow is realized. The overall message: Cardinal is deliberately in “investment mode,” with the balance sheet still healthy but not overstuffed.
Near-Term Headwinds in Nuclear Comparisons
In the nuclear segment, Cardinal flagged a near-term challenge in the form of tougher year-over-year comparisons in the third quarter. The business is lapping a period of particularly strong Theranostics growth, which could make upcoming growth rates appear softer even if the business remains fundamentally healthy. Management presented this as a timing and base-effects issue rather than a structural concern, but it is a factor for investors modeling quarterly trends in this otherwise high-growth business.
Guidance and Outlook: Growth Engines Firing Across the Portfolio
Looking ahead, Cardinal Health’s updated guidance paints a picture of sustained momentum across its key segments. The company now expects fiscal 2026 non-GAAP EPS of $10.15–$10.35, up from prior guidance of at least $10, underpinned by 19% revenue growth in the quarter, a 24% increase in gross margin, and a 38% jump in operating earnings. Pharma and Specialty segment profit growth is now forecast at 20%–22%, up from 16%–19% previously, reflecting the strength of specialty and GLP-1 volumes. GNPD is expected to deliver 1%–3% revenue growth with segment profit around $150 million, signaling continued but measured improvement. Other growth businesses are projected to grow revenue by 26%–28% and profit by 33%–35%, slightly below earlier revenue expectations but with stronger profitability. Cardinal also guided to a 21%–23% tax rate, diluted shares of about 237–238 million, and adjusted free cash flow of $3.0–$3.5 billion, all underpinned by a leverage ratio of 3.2x comfortably within its targeted band. The outlook underscores a balanced story of growth, margin resilience, and disciplined capital deployment.
In sum, Cardinal Health’s earnings call delivered a confident message of broad-based growth, improving margins, and rising earnings power, anchored by its pharma and specialty franchise and complemented by accelerating “other” growth platforms. While investors must weigh ongoing pressures from tariffs, higher interest costs, and some temporary volume and comparison headwinds, the company’s upgraded guidance and strengthened balance sheet suggest it is well positioned to navigate these challenges. For market participants tracking the healthcare distribution and specialty landscape, Cardinal Health appears to be transitioning from a defensive player to a more offensive, growth-driven story.
